Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБОУ ВО Санкт-Петербургский государственный университет. 199034, Россия, Санкт-Петербург, Университетская наб., д. 7/9; 2ФГБУ Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева. 192019, Россия, Санкт-Петербург, ул. Бехтерева, д. 3
Depression in women during the menopausal transition
G.E.Mazo1,2, M.A.Ganzenko2 1Saint Petersburg State University. 199034, Russian Federation, Saint Petersburg, Universitetskaia nab., d. 7/9; 2V.M.Bekhterev Saint Petersburg Research Institute. 192019, Russian Federation, Saint Petersburg, ul. Bekhtereva, d. 3
Список исп. литературыСкрыть список 1. Harlow SD, Gass M, Hall JE et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Climacteric 2012; 15 (2): 105–14. 2. Matthews KA, Crawford SL, Chae CU et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition. J Am Coll Cardiol 2009; 54: 2366–73. 3. Finkelstein JS, Brockwell SE, Mehta V et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008; 93: 861–8. 4. Neves-e-Castro M, Birkhauser M, Samsioe G et al. EMAS position statement: The ten point guide to the integral management of menopausal health. Maturitas 2015. http://dx.doi.org/10.1016 /j.maturitas.2015.02.003 5. Jaspers L, Daan NMP, van Dijk GM et al. Health in middle-aged and elderly women: A conceptual framework for healthy menopause. Maturitas 2015. http://dx.doi.org/10.1016/j.maturitas.2015.02.010 6. Gibbs Z et al. Factors Associated with Depression During the Perimenopausal Transition. Women's Health Issues 2013; 23 (5): 301–7. 7. National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005; 142: 1003–13. 8. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006; 63: 375–82. 9. Avis NE, Brambilla D, McKinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women’s Health Study. Ann Epidemiol 1994; 4: 214–20. 10. Freeman EW, Sammel MD, Liu L et al. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004; 61: 62–70. 11. Deecher D, Andree TH et al. From menarche to menopause: Exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology 2008; 33: 3–17. 12. Bromberger JT, Schott LL, Kravitz HM et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women’s Health Across the Nation (SWAN). Arch Gen Psychiatry 2010; 67: 598–607. 13. Llaneza P, Garcia-Portilla MP et al. Depressive disorders and the menopause transition. Maturitas 2012; 71: 120–30. 14. Graziottin A, Serafini A.Depression and the menopause: why antidepressants are not enough? Menopause Int 2009; 15 (2): 76–81. 15. Lokuge S, Frey BN, Foster JA et al. Depression in women: windows of vulnerability and new insights into the link between estrogen and serotonin. J Clin Psychiatry 2011; 72 (11): 1563–9. 16. Rubinow DR, Roca CA, Schmidt PJ. Estrogens and depression in women. In R.A.Lobo (Ed.). Treatment of the postmenopausal woman: Basic and clinical aspects. NewYork: Elsevier. 2007; p. 307–23. 17. Hale GE, Robertson DM, Burger HG. The perimenopausal woman: endocrinology and management. J Steroid Biochem Mol Biol 2014; 142: 121–31. 18. Soares J, Masana M, Ershahin C, Dubocovich M. Functional melatonin receptors in rat ovaries at various stages of the estrous cycle. J Pharmacol Exp Ther 2003; 306: 694–702. 19. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977; 4: 31–47. 20. Worsley R, Bell R, Kulkarni J. The association between vasomotor symptoms and depression duringperimenopause: A systematic review. Maturitas 2014; 77: 111–7. 21. Judd FK, Hickey M et al. Depression and midlife: Are we overpathologising the menopause? J Affect Dis 2012; 136: 199–211. 22. Ozturk O, Eraslan D, Mete HE, Ozsener S. The risk factors and symptomatology of perimenopausal depression. Maturitas 2006; 55: 180–6. 23. Kornstein SG, Young EA, Harvey AT et al. The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women. Menopause 2010; 17: 828–39. 24. Worsley R, Davis SR, Gavrilidis E et al. Hormonal therapies for new onset and relapsed depression during perimenopause. Maturitas 2012; 73: 127–33. 25. Bezerra AG, Andersen ML et al. Approach towards mild depression: Shortest way to treat climacteric syndrome? Maturitas 2013; 74: 105. 26. Soares CN, Poitras JR, Prouty J et al. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry 2003; 64 (4): 473–9. 27. Joffe H, Soares CN, Petrillo LF et al. Treatment of depression and menopause-related symptoms with the serotoninnorepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry 2007; 68: 943–50. 28. Richards JB, Papaioannou A, Adachi JD et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Int Med 2007; 167: 188–94. 29. Jacka FN, Pasco JA, Henry MJ et al. Depression and bone mineral density in a community sample of perimenopausal women: Geelong Osteoporosis Study. Menopause 2005; 12: 88–91. 30. Montejo AL, Llorca G, Izquierdo JA et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62 (Suppl. 3): 10–21. 31. Davis SR, Jane F. Sex and perimenopause. Australian Family Physician 2011; 40: 274–8. 32. Azarbad L, Gonder-Frederick L. Obesity in Women. Psychiatr Clin North Am 2010; 33 (Issue 2): 423–40. 33. Мазо Г.Э., Шманева Т.М., Соколян Н.А. Факторы риска фармакогенной прибавки веса у пациентов с депрессивным расстройством. Психические расстройства в общей медицине. 2013; 1: 15–21. / Mazo G.E., Shmaneva T.M., Sokolian N.A. Faktory riska farmakogennoi pribavki vesa u patsientov s depressivnym rasstroistvom. Mental Disorders in General Medicine. 2013; 1: 15–21. [in Russian] 34. Morgan ML, Cook IA, Rapkin A., Leuchter AF. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry 2005; 66 (6): 774–80. 35. Claghorn J, Earl C, Walczak D. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 1996; 16 (2): 113–20. 36. Незнамов Г.Г., Сюняков С.А., Телешева Е.С. Терапевтическое действие и эффективность феварина (флувоксамина) у больных с непсихотическими тревожными и апато-адинамическими депрессиями. Журн. неврологии и психиатрии им. С.С.Корсакова. 2001; 8; 19–24. / Neznamov G.G., Siuniakov S.A., Telesheva E.S. Terapevticheskoe deistvie i effektivnost' fevarina (fluvoksamina) u bol'nykh s nepsikhoticheskimi trevozhnymi i apato-adinamicheskimi depressiiami. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2001; 8; 19–24. [in Russian] 37. Serretti A, Mandelli L. Antidepressants and Body Weight: A Comprehensive Review and Meta-Analysis. J Clin Psychiatry 2010; 71 (10): 1259–72. 38. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacology 2009; 29 (3): 259–66. 39. Harrod CG, Bendok BR, Batjer YY. Interactions between melatonin and estrogen may regulate cerebrovascular function in women: clinical implications for the effective use of HRT during menopause and aging. Med Hypotheses 2005; 64: 725–35. 40. Анисимов В.Н., Виноградова И.А. Старение женской репродуктивной системы и мелатонин. СПб.: Система, 2008. / Anisimov V.N., Vinogradova I.A. Starenie zhenskoĭ reproduktivnoĭ sistemy i melatonin. SPb.: Sistema, 2008. [in Russian] 41. Антонова А.А., Бачило Е.В., Барыльник Ю.Б. Современный взгляд на проблему развития психических расстройств у женщин в перименопаузе (обзор). Саратовский науч.-мед. журн. 2012; 8 (2): 379–83. / Antonova A.A., Bachilo E.V., Baryl'nik Iu.B. Sovremennyi vzgliad na problemu razvitiia psikhicheskikh rasstroistv u zhenshchin v perimenopauze (obzor). Saratovskii nauch.-med. zhurn. 2012; 8 (2): 379–83. [in Russian] 42. Hansena MV, Danielsenb AK, Hagemanc I et al. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: A systematic review and meta-analysis. Eur Neuropsychopharmacol 2014; 24: 1719–28. 43. Hartter S, Himing H, Weigman H et al. Pharmacological differences-cal effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol 2001; 21: 167–74. 44. Oishi A, Mochizuki Y et al. Pilot study of fluvoxamine treatment for climacteric symptoms in Japanese women. Bio Psycho Social Med 2007; 1 (12): 1–4. 45. NICE, 2009. Depression: the treatment andmanagement of depression in adults (NICE clinical guideline 90). Available: http://guidance.nice.org.uk/CG90. 46. Lacroix AZ, Freeman EW, Larson J et al. Effects of escitalopram on menopausespecific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. Maturitas 2012, 73 (4): 361–8. 47. Parry BL. Optimal management of perimenopausal depression. Int J Women’s Health 2010; 2: 143–51. 48. Palinkas LA, Barrett-Connor E. Estrogen use and depressive symptoms in postmenopausal women. Obstet Gynecol 1992; 80 (1): 30–6. 49. Rasgon NL, Altshuler LL, Fairbanks LA et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry 2002; 63 (Suppl. 7): 45–8. 50. Cohen LS, Soares CN, Poitras JR et al. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: A preliminary report. Am J Psychiatry 2003; 160 (8): 1519–22. 51. Prange AJ, Wilson IC, Alltop LB. Estrogen may well affect response to antidepressant. JAMA 1972; 219: 143–4. 52. Liu P, He FF, Bai WP et al. Menopausal depression: Comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine. Chin Med J (Engl). 2004; 117 (2): 189–94. 53. Schneider LS, Small GW, Clary CM. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry 2001; 9 (4): 393–9.